Pharmacokinetics and pharmacodynamics of ticagrelor in the treatment of cardiac ischemia

References

• Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001 Aug 16;345(7):494–502.
   PubMed Web of Science ®Google Scholar
• Perk J, De Backer G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the fifth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Int J Behav Med. 2012;19:403–488.
   PubMed Web of Science ®Google Scholar
• Bassand JP, Hamm CW, Ardissino D, et al. Task force for diagnosis and treatment of non-st-segment elevation acute coronary syndromes of european society of cardiology, Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28:1598–1660.
   PubMed Web of Science ®Google Scholar
• Mehta RS, Yusuf S, Peters JG, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527–533.
   PubMed Web of Science ®Google Scholar
• Jernberg T, Hasvold P, Henriksson M, et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015 May 14;36(19):1163–1170.
   PubMed Web of Science ®Google Scholar
• Husted S, van Giezen JJ. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther. 2009;27:259–274.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist compared with clopidogrl in patients with non-ST segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol. 2007;50:1844–1851.
   PubMed Web of Science ®Google Scholar
• Husted S, Emanulesson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics,and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with a atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006;27:1038–1047.
   PubMed Web of Science ®Google Scholar
• van Giezen JJ, Nilsson L, Berntsson P, et al. Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost. 2009;7:1556–1565.
   PubMed Web of Science ®Google Scholar
• van Giezen JJ, Sidaway J, Glaves P, et al. Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model. J Cardiovasc Pharmacol Ther. 2012;17:164–172.
   PubMed Web of Science ®Google Scholar
• Wittfeldt A, Emanuelsson H, Brandrup-Wognsen G, et al. Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans. J Am Coll Cardiol. 2013;61:723–727.
   PubMed Web of Science ®Google Scholar
• Armstrong D, Summers C, Ewart L, et al. Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1. J Cardiovasc Pharmacol Ther. 2014;19:209–219.
   PubMed Web of Science ®Google Scholar
• Cattaneo M, Schulz R, Nylander S. Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J Am Coll Cardiol. 2014 Jun 17;63(23):2503–2509.
   PubMed Web of Science ®Google Scholar
• Nylander S, Schultz R. Effects of P2Y (12) receptor antagonists beyond platelet inhibition- comparison of ticagrelor with thienopyridines. Br J Pharmacol. 2016 Apr;173(7):1163–1178.
   PubMed Web of Science ®Google Scholar
• Teng R, Oliver S, Hayes MA, et al. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos. 2010;38:1514–1521.
   PubMed Web of Science ®Google Scholar
• Holmberg MT, Tornio A, Joutsi-Korhonen L, et al. Grapefruit juice markedly increases the plasma concentrations and antiplatelet effects of ticagrelor in healthy subjects. Br J Clin Pharmacol. 2013;15:1488–1496.
   Web of Science ®Google Scholar
• Husted S, Storey RF, Bliden K, et al. Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET/OFFSET and RESPOND studies. Clin Pharmacokinet. 2012;51:397–409.
   PubMed Web of Science ®Google Scholar
• Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol. 2007;50:1852–1856.
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Xanthopoulou I, Gkizas V, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv. 2012;5:797–804.
   PubMed Web of Science ®Google Scholar
• Parodi G, Valenti R, Bellandi B, et al. Comparison of prasugrel and ticagrelor loading dose s in ST-segment elevation myocardial infaction patients: RAPID (Rapid Activity of Platelet Inhibitors Drugs) primary PCI study. J Am Coll Cardiol. 2013;61:1601–1606.
   PubMed Web of Science ®Google Scholar
• Butler K, Teng R. Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with severe renal impairment. J Clin Pharmacol. 2012;52:1388–1398.
   PubMed Web of Science ®Google Scholar
• Butler K, Teng R. Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with mild hepatic impairment. J Clin Pharmacol. 2011;51:978–987.
   PubMed Web of Science ®Google Scholar
• Teng R, Butler K. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. Eur J Clin Pharmacol. 2010;66:487–496.
   PubMed Web of Science ®Google Scholar
• Butler K, Teng R. Pharmacokinetics, pharmacodynamics safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. Br J Clin Pharmacol. 2010;70:65–77.
   PubMed Web of Science ®Google Scholar
• Teng R, Mitchell P, Butler K. Effect of age and gender on pharmacokinetics and pharmacodynamics of a single ticagrelor dose in healthy individuals. Eur J Clin Pharmacol. 2012;68:1175–1182.
   PubMed Web of Science ®Google Scholar
• Zhou D, Andersson TB, Grimm SW. In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics. Drug Metab Dispos. 2011;39:703–710.
   PubMed Web of Science ®Google Scholar
• Teng R, Mitchell PD, Butler KA. Pharmacokinetic interaction studies of administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers. Eur J Clin Pharmacol. 2013;69:477–487.
   PubMed Web of Science ®Google Scholar
• Teng R, Mitchell P, Butler K. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy subjects. Eur J Clin Pharmacol. 2013;69:877–883.
   PubMed Web of Science ®Google Scholar
• Teng R, Butler K. Effect of the CYP3A inhibitors, diltiazem and ketoconazole, on ticagrelor pharmacokinetics in healthy volunteers. J Drug Assess. 2013;2:30–39.
   PubMedGoogle Scholar
• Teng R, Butler K. A pharmacokinetic interaction study of ticagrelor and digoxin in healthy volunteers. Eur J Clin Pharmacol. 2013 Oct;69(10):1801–1808.
   PubMed Web of Science ®Google Scholar
• Teng R, Kujacic M, Hsia J. Pharmacokinetic interaction study of ticagrelor and cyclosporine in healthy volunteers. Clin Drug Investig. 2014;34:529–536.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Butler K, et al. Randomized doubleblind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009;120:2577–2585.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Butler K, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation. 2010;121:1188–1199.
   PubMed Web of Science ®Google Scholar
• Li J, Tang W, Storey RF, et al. Population pharmacokinetics of ticagrelor in patients with acute coronary syndromes. Int J Clin Pharmacol Ther. 2016 May 18;54:666–674. Epub ahead of print. DOI: 10.5414/CP202549
   PubMed Web of Science ®Google Scholar
• Li H, Guo J, Carlson GF, et al. Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease. Br J Clin Pharmacol. 2016 Aug;82(2):352–361. Epub 2016 Jun 9. DOI:10.1111/bcp.12950
   PubMed Web of Science ®Google Scholar
• Kubica J, Adamski P, Ostrowska M, et al. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J. 2016 Jan 14;37(3):245–252.
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–1057.
   PubMed Web of Science ®Google Scholar
• Lindholm D, Varenhorst C, Cannon CP, et al. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. Eur Heart J. 2014;35:2083–2093.
   PubMed Web of Science ®Google Scholar
• Steg PG, Harrington RA, Emanuelsson H, et al. Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective randomized PLATO trial. Circulation. 2013 Sep 3;128(10):1055–1065.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706–1717.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49:1982–1988.
   PubMed Web of Science ®Google Scholar
• Mauri L, Kereiakes DJ, Normand SL, et al. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am Heart J. 2010;160:1035–1041.
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Bhatt DL, Braunwald E, et al. Design and rationale for the prevention of cardiovascular events in patients with prior heart attack using ticagrelor compared to placebo on a background of aspirin-thrombolysis in myocardial infarction 54 (PEGASUS-TIMI 54) Trial. Am Heart J. 2014;167:437–444.
   PubMed Web of Science ®Google Scholar
• Anonymous. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. the GUSTO investigators. N Engl J Med. 1993;329:673–682.
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C. Subcommittee on control of anticoagulation of the scientific and standardization committee of the international society on thrombosis and haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in nonsurgical patients. J Thromb Haemost. 2005;3:692–694.
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791–1800.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Bonaca MP, Bansilal S, et al. Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS-TIMI 54. J Am Coll Cardiol. 2016 Jun 14;67(23):2732–2740. Epub 2016 Apr 1. DOI:10.1016/j.jacc.2016.03.529
   PubMed Web of Science ®Google Scholar
• Magnani G, Storey RF, Steg G, et al. Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. Eur Heart J. 2016 Jan 21;37(4):400–408. Epub 2015 Oct 5. DOI:10.1093/eurheartj/ehv482
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Bhatt DL, Storey RF, et al. Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease. J Am Coll Cardiol. 2016 Jun 14;67(23):2719–2728. Epub 2016 Apr 1. DOI:10.1016/j.jacc.2016.03.524
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Bhatt DL, Steg PG, et al. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. Eur Heart J. 2016 Apr 7;37(14):1133–1142. Epub 2015 Oct 21. DOI:10.1093/eurheartj/ehv531
   PubMed Web of Science ®Google Scholar
• Mauri L, Kerelakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug eluting stents. N Eng J Med. 2014;371(23):2155–2166.
   PubMed Web of Science ®Google Scholar
• James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the platelet inhibition and patient outcomes (PLATO) trial. Circulation. 2010;122:1056–1067.
   PubMed Web of Science ®Google Scholar
• Hansson EC, Jideus L, Aberg B, et al. Coronary artery bypass grafting-related bleeding complications in patients treated with ticagrelor or clopidogrel: a nationwide study. Eur Heart J. 2016 Jan 7;37(2):189–197.
   PubMed Web of Science ®Google Scholar
• Bonello L, Laine M, Kipson N, et al. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. J Am Coll Cardiol. 2014 Mar 11;63(9):872–877.
   PubMed Web of Science ®Google Scholar
• Fromonot J, Dignat-Georges F, Rossi P, et al. Ticagrelor improves peripheral arterial function in acute coronary syndrome patients: relationship with adenosine plasma level. J Am Coll Cardiol. 2016 Apr 26;67(16):1967–1968.
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Stebbing J, Atar D. Dyspnoea after antiplatelet agents: the AZD6140 controversy. Int J Clin Pract. 2007;61:529–533.
   PubMed Web of Science ®Google Scholar
• Cattaneo M, Faioni E. Why does ticagrelor induce dyspnea? Thromb Haemost. 2012;108:1031–1036.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Cannon CP, Emanuelsson H, et al. The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagreloror clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy. J Am Coll Cardiol. 2011;57:1908–1916.
   PubMed Web of Science ®Google Scholar
• Belardinelli L, Shryock JC, Song Y, et al. Ionic basis of the electrophysiological actions of adenosine on cardiomyocytes. Faseb J. 1995;9:359–365.
   PubMed Web of Science ®Google Scholar
• Zaza A, Rocchetti M, DiFrancesco D. Modulation of the hyperpolarization activated current (If) by adenosine in rabbit sinoatrial myocytes. Circulation. 1996;94:734–741.
   PubMed Web of Science ®Google Scholar
• Storey RF, Bliden KP, Patil SB, et al. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. J Am Coll Cardiol. 2010;56:185–193.
   PubMed Web of Science ®Google Scholar
• Butler K, Maya J, Teng R. Effect of ticagrelor on pulmonary function in healthy elderly volunteers and asthma or chronic obstructive pulmonary disease patients. Curr Med Res Opin. 2013;29:569–577.
   PubMed Web of Science ®Google Scholar
• Andell P, James SK, Cannon CP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes and chronic obstructive pulmonary disease: an analysis from the Platelet Inhibition and Patient Outcomes (PLATO) trial. J Am Heart Assoc. 2015 Oct;4(10):e002490.
   PubMed Web of Science ®Google Scholar
• Storey RF, Becker RC, Harrington RA, et al. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. Eur Heart J. 2011;32:2945–2953.
   PubMed Web of Science ®Google Scholar
• Karazniewicz-Łada M, Danielak D, Gł_owka F. Genetic and non-genetic factors affecting the response to clopidogrel therapy. Expert Opin Pharmacother. 2012;13:663–683.
   PubMed Web of Science ®Google Scholar
• Tantry US, Bliden KP, Wei C, et al. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. Circ Cardiovasc Genet. 2010;3:556–566.
   PubMed Web of Science ®Google Scholar
• Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010;376:1320–1328.
   PubMed Web of Science ®Google Scholar
• Storey RF, Melissa Thornton S, Lawrance R, et al. Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3. Platelets. 2009;20:341–348.
   PubMed Web of Science ®Google Scholar
• Keaney JF. Balancing the risks and benefits of dual platelet inhibition. N Engl J Med. 2015 May 7;372(19):1854–1856.
   PubMed Web of Science ®Google Scholar
• Levine GN, Bates ER, Bittl JA, et al. ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2016;01699-5(16):S0735- S1097. 2016 Mar 23. Epub ahead of print. DOI:10.1016/j.jacc.2016.03.513
   Google Scholar
• Varenhorst C, Eriksson N, Johansson A, et al. Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. Eur Heart J. 2015 Aug 1;36(29):1901–1912.
   PubMed Web of Science ®Google Scholar